Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPOPO: Paclitaxel or Cisplatin with Oncothermia for Recurrent Ovarian Cancer
NCT02344095Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2014
- Primary completion
- Oct 2017
- Modality
- Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Paclitaxel Micelles for Injection and Cisplatin micelle injection (HA132) in epithelial ovarian carcinoma (EOC), fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Dose-Limiting Toxicity at 1 year. Started Dec 2014; status: completed.
02
Drugs
Paclitaxel Micelles for InjectionCisplatin micelle injection (HA132)
03
Conditions
epithelial ovarian carcinoma (EOC)fallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02344095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02344095.